The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.
 
Oddbjorn Straume
Travel, Accommodations, Expenses - BerGenBio; Pierre Fabre
 
Cornelia Schuster
No Relationships to Disclose
 
Gro Gausdal
Employment - BerGenBio
 
James Lorens
Stock and Other Ownership Interests - BerGenBio
 
Bjorn T. Gjertsen
Leadership - Alden Cancer Therapy II; Kinn Therapeutics
Stock and Other Ownership Interests - Alden Cancer Therapy II; Kinn Therapeutics
Consulting or Advisory Role - BerGenBio; Novartis; Seagen
Research Funding - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Alden Cancer Therapy II patent application in relation to CryoIT trial.
Travel, Accommodations, Expenses - Novartis; Seagen